Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
A biologic drug derived from enzymatic hydrolysis of porcine brain tissue, containing low-molecular-weight peptides and free amino acids. Manufactured by EVER Pharma and registered in 50+ countries (not FDA-approved in the US) for ischemic stroke, TBI, and dementia.
Lowest Price
$68.00
Highest Price
$106.00
Average Price
$87.00
Potential Savings
94%
across 2 options
0 of 2 vendors are lab-verified for Cerebrolysin
We cross-check each vendor's Certificate of Analysis against the issuing lab's own verification portal — so “cheapest” isn't the only signal.
Best price trend
Lowest $/mg for Cerebrolysin · last 45 days
$1.05/mg
▼ 16% vs 45d ago
Trust grade first, cheapest within grade
vial · 600mgzztai-tech.com· price updated today
$0.113/mg
vial · 60mgmyoasislabs.com· price updated today
$1.77/mg
94% more per mg
vial · 60mgpeptidetech.co· price updated 2d ago
$1.25/mg
91% more per mg
vial · 60mgamc-essentials.com· price updated today
$0.833/mg
86% more per mg
vial · 60mgsouthernaminos.com· price updated today
$79.00−25%
$59.25$0.988/mg
89% more per mg
Prices are estimates and may vary. For research use only. We may earn a commission on purchases through affiliate links. Not medical advice.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Every vendor on this page is verified for endotoxin testing — not just HPLC purity.
The CASTA trial (Heiss et al., Stroke 2012, PMID 22282884, n=1070) failed its primary endpoint in Asian ischemic stroke patients, though a post-hoc subgroup with NIHSS >12 showed favorable mortality and functional trends. The CARS trial (Muresanu et al., Stroke 2016, PMID 26564102) reported improved upper-extremity motor recovery at day 90 with 30 mL/d for 21 days alongside rehabilitation. The Guekht 2011 vascular-dementia RCT (PMID 20656516, n=242) reported ADAS-cog+ and CIBIC+ improvements vs placebo. A 2023 Cochrane review (Ziganshina et al., PMID 37818733) concluded moderate-certainty evidence that Cerebrolysin/Cerebrolysin-like peptide mixtures probably do not reduce all-cause death in acute ischemic stroke, and flagged a possible increase in non-fatal serious adverse events. Many pivotal trials are industry-sponsored, and batch-to-batch variability as a porcine-brain hydrolysate is an ongoing methodological concern.
This platform provides informational tools only, not medical advice.
Heiss WD et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke 2012;43(3):630-636
2012
Muresanu DF et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke 2016;47(1):151-159
2016
Guekht AB et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 2011;20(4):310-318
Prices verified as of June 2026. Actual prices may vary. For research use only.
2011
Disclosed Labs